OncLive TV

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Barbara Ann Karmanos Cancer Institute, discusses research questions with Lutathera in the treatment of patients with neuroendocrine tumors.

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses targeted agents in chronic lymphocytic leukemia (CLL).

Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

Robert C. Garrett, FACHE, chief executive officer, Hackensack Meridian Health, discusses the significance of John Theurer Cancer Center joining the Georgetown Lombardi Cancer Consortium.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses patient selection in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses key data with immunotherapy in metastatic bladder cancer.

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

Gazala N. Khan, MD, gastrointestinal medical oncologist, Henry Ford Health System, discusses sequencing strategies in advanced hepatocellular carcinoma.

Giuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses emerging combination therapies in hepatocellular carcinoma (HCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the data with the combination of axitinib (Inlyta) and avelumab (Bavencio) in advanced renal cell carcinoma (RCC).

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of targeted therapy in non–small cell lung cancer.

Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing work with immunotherapy in patients with advanced ovarian cancer.

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the data behind the potential link between cardiac complications and androgen deprivation therapy (ADT) in prostate cancer.

Saurabh Chhabra, MD, MS, assistant professor at the Medical College of Wisconsin, discusses the most impactful advances made in relapsed/refractory multiple myeloma.

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses ongoing research with ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the significance of becoming a National Cancer Institute-designated cancer center.

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the biology of renal cell carcinoma (RCC).

Se Ik Kim, MD, research fellow, Department of Obstetrics and Gynecology, Seoul National University Hospital, discusses the use of minimally invasive surgery and laparotomic surgery in patients with cervical cancer.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.